You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 18, 2025

VELTASSA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Veltassa, and when can generic versions of Veltassa launch?

Veltassa is a drug marketed by Vifor Pharma and is included in one NDA. There are eight patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred patent family members in twenty-seven countries.

The generic ingredient in VELTASSA is patiromer sorbitex calcium. One supplier is listed for this compound. Additional details are available on the patiromer sorbitex calcium profile page.

DrugPatentWatch® Generic Entry Outlook for Veltassa

Veltassa was eligible for patent challenges on October 21, 2019.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 29, 2030. This may change due to patent challenges or generic licensing.

There have been two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Try for Free

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for VELTASSA?
  • What are the global sales for VELTASSA?
  • What is Average Wholesale Price for VELTASSA?
Drug patent expirations by year for VELTASSA
Drug Prices for VELTASSA

See drug prices for VELTASSA

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for VELTASSA
Generic Entry Date for VELTASSA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
POWDER;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for VELTASSA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of California, IrvinePhase 4
NHS Greater Glasgow and ClydePhase 4
University of GlasgowPhase 4

See all VELTASSA clinical trials

Pharmacology for VELTASSA
Drug ClassPotassium Binder
Mechanism of ActionPotassium Ion Binding Activity
Paragraph IV (Patent) Challenges for VELTASSA
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
VELTASSA for Oral Suspension patiromer sorbitex calcium 8.4 g, 16.8 g and 25.2 g 205739 2 2019-10-21

US Patents and Regulatory Information for VELTASSA

VELTASSA is protected by eight US patents and two FDA Regulatory Exclusivities.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of VELTASSA is ⤷  Try for Free.

This potential generic entry date is based on patent ⤷  Try for Free.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Vifor Pharma VELTASSA patiromer sorbitex calcium POWDER;ORAL 205739-003 Oct 21, 2015 DISCN Yes No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Vifor Pharma VELTASSA patiromer sorbitex calcium POWDER;ORAL 205739-003 Oct 21, 2015 DISCN Yes No ⤷  Try for Free ⤷  Try for Free Y ⤷  Try for Free
Vifor Pharma VELTASSA patiromer sorbitex calcium POWDER;ORAL 205739-003 Oct 21, 2015 DISCN Yes No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Vifor Pharma VELTASSA patiromer sorbitex calcium POWDER;ORAL 205739-003 Oct 21, 2015 DISCN Yes No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Vifor Pharma VELTASSA patiromer sorbitex calcium POWDER;ORAL 205739-004 Oct 2, 2023 RX Yes No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Vifor Pharma VELTASSA patiromer sorbitex calcium POWDER;ORAL 205739-001 Oct 21, 2015 RX Yes No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for VELTASSA

International Patents for VELTASSA

When does loss-of-exclusivity occur for VELTASSA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 09282721
Patent: Crosslinked cation exchange polymers, compositions and use in treating hyperkalemia
Estimated Expiration: ⤷  Try for Free

Brazil

Patent: 0917853
Patent: composição farmacêutica, polímero reticulado de troca catiônica ou uma composição farmacêutica para remover potássio do trato gastrointestinal, polímetro carboxílico alifático reticulado estabilizado de poliol linear, e, método para fazer um polímetro reticulado de troca catiônica
Estimated Expiration: ⤷  Try for Free

Canada

Patent: 35058
Patent: POLYMERES RETICULES ECHANGEURS CATIONIQUES, COMPOSITIONS ET UTILISATION DANS LE TRAITEMENT DE L'HYPERKALIEMIE (CROSSLINKED CATION EXCHANGE POLYMERS, COMPOSITIONS AND USE IN TREATING HYPERKALEMIA)
Estimated Expiration: ⤷  Try for Free

China

Patent: 2202670
Patent: Crosslinked cation exchange polymers, compositions and use in treating hyperkalemia
Estimated Expiration: ⤷  Try for Free

Patent: 3919792
Patent: Crosslinked Cation Exchange Polymers, Compositions And Use In Treating Hyperkalemia
Estimated Expiration: ⤷  Try for Free

Croatia

Patent: 0150955
Estimated Expiration: ⤷  Try for Free

Patent: 0181961
Estimated Expiration: ⤷  Try for Free

Patent: 0230091
Estimated Expiration: ⤷  Try for Free

Cyprus

Patent: 16850
Estimated Expiration: ⤷  Try for Free

Patent: 20930
Estimated Expiration: ⤷  Try for Free

Patent: 18002
Estimated Expiration: ⤷  Try for Free

Patent: 19002
Estimated Expiration: ⤷  Try for Free

Denmark

Patent: 65988
Estimated Expiration: ⤷  Try for Free

Patent: 57286
Estimated Expiration: ⤷  Try for Free

Patent: 31094
Estimated Expiration: ⤷  Try for Free

European Patent Office

Patent: 65988
Patent: POLYMÈRES RÉTICULÉS ÉCHANGEURS CATIONIQUES, COMPOSITIONS ET UTILISATION DANS LE TRAITEMENT DE L'HYPERKALIÉMIE (CROSSLINKED CATION EXCHANGE POLYMERS, COMPOSITIONS AND USE IN TREATING HYPERKALEMIA)
Estimated Expiration: ⤷  Try for Free

Patent: 57286
Patent: COMPOSITIONS COMPRENANT DES POLYMERES RETICULES ECHANGEURS CATIONIQUES ET UTILISATION DANS LE TRAITEMENT DE L'HYPERKALIEMIE (COMPOSITIONS COMPRISING CROSSLINKED CATION EXCHANGE POLYMERS AND USE IN TREATING HYPERKALEMIA)
Estimated Expiration: ⤷  Try for Free

Patent: 31094
Patent: POLYMÈRES D'ÉCHANGE DE CATIONS RÉTICULÉS, COMPOSITIONS ET UTILISATION DANS LE TRAITEMENT DE L'HYPERKALIÉMIE (CROSSLINKED CATION EXCHANGE POLYMERS, COMPOSITIONS AND USE IN TREATING HYPERKALEMIA)
Estimated Expiration: ⤷  Try for Free

Patent: 01408
Patent: POLYMÈRES RÉTICULÉS ÉCHANGEURS DE CATIONS, COMPOSITIONS ET UTILISATION DANS LE TRAITEMENT DE L'HYPERKALIÉMIE (CROSSLINKED CATION EXCHANGE POLYMERS, COMPOSITIONS AND USE IN TREATING HYPERKALEMIA)
Estimated Expiration: ⤷  Try for Free

Finland

Patent: 31094
Estimated Expiration: ⤷  Try for Free

Germany

Patent: 2009002063
Estimated Expiration: ⤷  Try for Free

Hong Kong

Patent: 84675
Patent: CROSSLINKED CATION EXCHANGE POLYMERS, COMPOSITIONS AND USE IN TREATING HYPERKALEMIA
Estimated Expiration: ⤷  Try for Free

Hungary

Patent: 25934
Estimated Expiration: ⤷  Try for Free

Patent: 61320
Estimated Expiration: ⤷  Try for Free

Patent: 800004
Estimated Expiration: ⤷  Try for Free

Patent: 900003
Estimated Expiration: ⤷  Try for Free

Japan

Patent: 56403
Estimated Expiration: ⤷  Try for Free

Patent: 83471
Estimated Expiration: ⤷  Try for Free

Patent: 32468
Estimated Expiration: ⤷  Try for Free

Patent: 33583
Estimated Expiration: ⤷  Try for Free

Patent: 90116
Estimated Expiration: ⤷  Try for Free

Patent: 12500806
Estimated Expiration: ⤷  Try for Free

Patent: 14144977
Patent: CATION-EXCHANGE CROSS-LINKED POLYMER AND COMPOSITION AND THE USE THEREOF IN TREATMENT OF HYPERKALEMIA
Estimated Expiration: ⤷  Try for Free

Patent: 14144978
Patent: CATION-EXCHANGE CROSS-LINKED POLYMER AND COMPOSITION AND THE USE THEREOF IN TREATMENT OF HYPERKALEMIA
Estimated Expiration: ⤷  Try for Free

Patent: 16145256
Patent: 架橋陽イオン交換ポリマー、組成物、および高カリウム血症の治療における使用 (CROSSLINKED CATION EXCHANGE POLYMERS, COMPOSITIONS AND USE IN TREATING HYPERKALEMIA)
Estimated Expiration: ⤷  Try for Free

Patent: 17218454
Patent: 架橋陽イオン交換ポリマー、組成物、および高カリウム血症の治療における使用 (CROSSLINKED CATION EXCHANGE POLYMERS, COMPOSITIONS AND USE IN TREATING HYPERKALEMIA)
Estimated Expiration: ⤷  Try for Free

Patent: 19065030
Patent: 架橋陽イオン交換ポリマー、組成物、および高カリウム血症の治療における使用 (CROSSLINKED CATION EXCHANGE POLYMERS, COMPOSITIONS AND USE IN TREATING HYPERKALEMIA)
Estimated Expiration: ⤷  Try for Free

Patent: 20172537
Patent: 架橋陽イオン交換ポリマー、組成物、および高カリウム血症の治療における使用 (CROSSLINKED CATION EXCHANGE POLYMERS, COMPOSITIONS AND USE IN TREATING HYPERKALEMIA)
Estimated Expiration: ⤷  Try for Free

Lithuania

Patent: 957286
Estimated Expiration: ⤷  Try for Free

Patent: 2018004
Estimated Expiration: ⤷  Try for Free

Patent: 2018016
Estimated Expiration: ⤷  Try for Free

Patent: 57286
Estimated Expiration: ⤷  Try for Free

Patent: 31094
Estimated Expiration: ⤷  Try for Free

Luxembourg

Patent: 0094
Estimated Expiration: ⤷  Try for Free

Mexico

Patent: 4398
Patent: POLIMEROS RETICULADOS DE INTERCAMBIO CATIONICO, COMPOSICIONES Y USO EN EL TRATAMIENTO DE LA HIPERCALCEMIA. (CROSSLINKED CATION EXCHANGE POLYMERS, COMPOSITIONS AND USE IN TREATING HYPERKALEMIA.)
Estimated Expiration: ⤷  Try for Free

Patent: 9664
Patent: POLIMEROS RETICULADOS DE INTERCAMBIO CATIONICO, COMPOSICIONES Y SU USO EN EL TRATAMIENTO DE LA HIPERCALCEMIA (CROSSLINKED CATION EXCHANGE POLYMERS, COMPOSITIONS AND USE IN TREATING HYPERKALEMIA)
Estimated Expiration: ⤷  Try for Free

Patent: 11001893
Patent: POLIMEROS RETICULADOS DE INTERCAMBIO CATIONICO, COMPOSICIONES Y USO EN EL TRATAMIENTO DE HIPERCALEMIA. (CROSSLINKED CATION EXCHANGE POLYMERS, COMPOSITIONS AND USE IN TREATING HYPERKALEMIA.)
Estimated Expiration: ⤷  Try for Free

Netherlands

Patent: 0962
Estimated Expiration: ⤷  Try for Free

Norway

Patent: 18004
Estimated Expiration: ⤷  Try for Free

Patent: 18041
Estimated Expiration: ⤷  Try for Free

Poland

Patent: 65988
Estimated Expiration: ⤷  Try for Free

Patent: 57286
Estimated Expiration: ⤷  Try for Free

Patent: 31094
Estimated Expiration: ⤷  Try for Free

Portugal

Patent: 65988
Estimated Expiration: ⤷  Try for Free

Patent: 57286
Estimated Expiration: ⤷  Try for Free

Patent: 31094
Estimated Expiration: ⤷  Try for Free

San Marino

Patent: 01500207
Estimated Expiration: ⤷  Try for Free

Patent: 01800660
Estimated Expiration: ⤷  Try for Free

Slovenia

Patent: 65988
Estimated Expiration: ⤷  Try for Free

Patent: 57286
Estimated Expiration: ⤷  Try for Free

Patent: 31094
Estimated Expiration: ⤷  Try for Free

South Korea

Patent: 1825113
Estimated Expiration: ⤷  Try for Free

Patent: 1928973
Estimated Expiration: ⤷  Try for Free

Patent: 2150184
Estimated Expiration: ⤷  Try for Free

Patent: 2178208
Estimated Expiration: ⤷  Try for Free

Patent: 2300471
Estimated Expiration: ⤷  Try for Free

Patent: 110063647
Patent: CROSSLINKED CATION EXCHANGE POLYMERS, COMPOSITIONS AND USE IN TREATING HYPERKALEMIA
Estimated Expiration: ⤷  Try for Free

Patent: 180014845
Patent: 가교결합된 양이온교환 폴리머, 조성물 및 고칼륨혈증 치료 용도 (CROSSLINKED CATION EXCHANGE POLYMERS COMPOSITIONS AND USE IN TREATING HYPERKALEMIA)
Estimated Expiration: ⤷  Try for Free

Patent: 180133561
Patent: 가교결합된 양이온교환 폴리머, 조성물 및 고칼륨혈증 치료 용도 (CROSSLINKED CATION EXCHANGE POLYMERS COMPOSITIONS AND USE IN TREATING HYPERKALEMIA)
Estimated Expiration: ⤷  Try for Free

Patent: 200029614
Patent: 가교결합된 양이온교환 폴리머, 조성물 및 고칼륨혈증 치료 용도 (CROSSLINKED CATION EXCHANGE POLYMERS COMPOSITIONS AND USE IN TREATING HYPERKALEMIA)
Estimated Expiration: ⤷  Try for Free

Patent: 200128600
Patent: 가교결합된 양이온교환 폴리머, 조성물 및 고칼륨혈증 치료 용도 (CROSSLINKED CATION EXCHANGE POLYMERS COMPOSITIONS AND USE IN TREATING HYPERKALEMIA)
Estimated Expiration: ⤷  Try for Free

Spain

Patent: 45887
Estimated Expiration: ⤷  Try for Free

Patent: 99494
Estimated Expiration: ⤷  Try for Free

Patent: 39021
Estimated Expiration: ⤷  Try for Free

United Kingdom

Patent: 75657
Patent: Crosslinked cation exchange polymers, compositions and use in treating hyperkalemia
Estimated Expiration: ⤷  Try for Free

Patent: 95426
Patent: Use of a crosslinked cation exchange polymer in removing potassium from the gastrointestinal tract of an animal
Estimated Expiration: ⤷  Try for Free

Patent: 95427
Patent: Use of a crosslinked cation exchange polymer in removing potassium from the gastrointestinal tract of an animal
Estimated Expiration: ⤷  Try for Free

Patent: 95428
Patent: Use of a crosslinked cation exchange polymer in removing potassium from the gastrointestinal tract of an animal
Estimated Expiration: ⤷  Try for Free

Patent: 1104561
Estimated Expiration: ⤷  Try for Free

Patent: 1222749
Estimated Expiration: ⤷  Try for Free

Patent: 1222750
Estimated Expiration: ⤷  Try for Free

Patent: 1222752
Estimated Expiration: ⤷  Try for Free

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VELTASSA around the world.

Country Patent Number Title Estimated Expiration
Cyprus 1116850 ⤷  Try for Free
Japan 2021095421 高血圧症及び高カリウム血症を治療するためのカリウム結合剤 (POTASSIUM BINDER FOR TREATING HYPERTENSION AND HYPERKALEMIA) ⤷  Try for Free
Japan 2019065030 架橋陽イオン交換ポリマー、組成物、および高カリウム血症の治療における使用 (CROSSLINKED CATION EXCHANGE POLYMERS, COMPOSITIONS AND USE IN TREATING HYPERKALEMIA) ⤷  Try for Free
Japan 6475624 ⤷  Try for Free
Canada 2558029 POLYMERES DE LIAISON IONIQUE ET LEURS UTILISATIONS (ION BINDING POLYMERS AND USES THEREOF) ⤷  Try for Free
Denmark 3219312 ⤷  Try for Free
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for VELTASSA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2957286 C02957286/01 Switzerland ⤷  Try for Free PRODUCT NAME: PATIROMER SORBITEX CALCIUM; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66411 22.12.2017
1732523 2018C/004 Belgium ⤷  Try for Free PRODUCT NAME: PATIROMER OF EENDER WELK ZOUT OF AFGELEIDE ERVAN; AUTHORISATION NUMBER AND DATE: EU/1/17/1179 20170721
2365988 PA2018004 Lithuania ⤷  Try for Free PRODUCT NAME: PATIROMERO, SORBITOLIO IR KALCIO KOMPLEKSAS IR JO DRUSKOS; REGISTRATION NO/DATE: EU/1/17/1179 20170719
2957286 C 2019 004 Romania ⤷  Try for Free PRODUCT NAME: PATIROMER SORBITEX SARE DE CALCIU; NATIONAL AUTHORISATION NUMBER: EU/1/17/1179/001-009; DATE OF NATIONAL AUTHORISATION: 20170719; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/17/1179/001-009; DATE OF FIRST AUTHORISATION IN EEA: 20170719
1732523 300924 Netherlands ⤷  Try for Free PRODUCT NAME: PATIROMER EN ALLE ZOUTEN DAARVAN; REGISTRATION NO/DATE: EU/1/17/1179/001-009 20170721
2957286 2018041 Norway ⤷  Try for Free PRODUCT NAME: PATIROMERSORBITEKSKALSIUM; REG. NO/DATE: EU/1/17/1179 20170809
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Market Dynamics and Financial Trajectory for Veltassa

Introduction

Veltassa, developed by Relypsa and later acquired by Vifor Pharma (now part of CSL Vifor), is a drug designed to treat hyperkalemia, a condition characterized by high potassium levels in the blood. This article delves into the market dynamics and financial trajectory of Veltassa, highlighting its sales performance, market positioning, and the factors influencing its financial success.

Development and Approval History

Veltassa was initially developed by Amgen and later transferred to Relypsa in 2009 for an upfront cost of $8.2 million. After its approval in 2015, Relypsa partnered with Vifor Fresenius Medical Care Renal Pharma to commercialize the drug outside the U.S. In 2016, Galenica (now Vifor Pharma) acquired Relypsa for $1.5 billion, marking a significant milestone in Veltassa's commercial journey[4].

Sales Performance

Quarterly Sales

Veltassa's sales have shown a mixed trajectory. Initially, the drug experienced slow growth in its early market years. However, its quarterly sales started increasing at a faster rate after the first year. By the fourth year on the market, Veltassa's quarterly sales surpassed $40 million, indicating a strong growth phase[1].

Annual Sales

In 2021, Veltassa's net sales were CHF 114.2 million, which represented a 3.5% decrease from the previous year, or a 1.0% decrease at constant exchange rates (CER). The U.S. market contributed significantly, with net sales amounting to CHF 95.3 million[2].

Comparative Sales Analysis

When compared to other drugs in the non-antimicrobial (non-AM) cohort, Veltassa's sales were notable but not exceptional. The drug's cumulative nine-quarter sales were lower than some of its peers, highlighting the variability in market performance within the cohort[1][3].

Market Dynamics

Competitive Landscape

Veltassa operates in a competitive market for hyperkalemia treatments. Despite its growth, the drug faces competition from other treatments and must continually demonstrate its clinical benefit to maintain market share. The overall comparative added clinical benefit score of Veltassa influences its sales, as drugs with higher scores tend to have higher early market sales[3].

Impact of COVID-19

The COVID-19 pandemic had a significant impact on the pharmaceutical industry, including Veltassa's sales. While the pandemic's effects were not specifically analyzed in the sales data, it is known that patient access to treatments was affected, leading to fluctuations in sales across various pharmaceutical products[1].

Financial Performance

Revenue Growth

Vifor Pharma, the parent company of Veltassa, reported sustained growth in 2021, with net sales increasing by 2.8% to CHF 1,754.2 million. Although Veltassa's sales decreased slightly in 2021, the overall portfolio performance was positive, driven mainly by the iron product portfolio[2].

EBITDA and Profit Margins

The company's EBITDA increased by 4.6% to CHF 602.0 million in 2021, reflecting strong operational performance and cost containment measures. The gross profit margin improved to 63.2%, primarily due to the higher share of sales from injectable iron products[2].

Cash Flow and Financial Position

Vifor Pharma maintained a strong financial position with a net cash position of CHF 453.8 million and an equity ratio of 77.8% at the end of 2021. The cash flow from operating activities increased to CHF +527.4 million, driven by positive developments in net working capital[2].

Strategic Moves and Partnerships

Commercialization Partnerships

Vifor Pharma's partnership with Fresenius Medical Care Renal Pharma for the commercialization of Veltassa outside the U.S. has been crucial for the drug's global reach. Additionally, partnerships in China and Canada for Veltassa and other products have contributed to the company's revenue growth[5].

Acquisitions and Divestments

The acquisition of Relypsa by Galenica in 2016 was a significant strategic move that integrated Veltassa into Vifor Pharma's portfolio. The divestment of non-core manufacturing sites and products has also been part of the company's strategy to focus on high-value assets[2].

Challenges and Opportunities

Clinical Benefit and Sales Correlation

While Veltassa's sales have been influenced by its clinical benefit score, there are exceptions and outliers. The drug's early market sales were lower than expected, but it has since shown growth. This highlights the need for continuous clinical validation and market positioning[1][3].

Market Expansion

The potential for Veltassa to expand into new markets and indications remains a significant opportunity. The drug's approval and commercialization in additional regions, such as China and Canada, have already contributed to its revenue growth[5].

Key Takeaways

  • Sales Growth: Veltassa's sales have shown a mixed trajectory, with significant growth after the first year but a slight decline in recent years.
  • Market Positioning: The drug operates in a competitive market and must continually demonstrate its clinical benefit to maintain market share.
  • Financial Performance: Vifor Pharma's overall financial performance has been strong, driven by its iron product portfolio and strategic partnerships.
  • Strategic Moves: Partnerships and acquisitions have been crucial for Veltassa's global reach and revenue growth.
  • Challenges and Opportunities: Continuous clinical validation and market expansion are key to Veltassa's future success.

FAQs

What is Veltassa used for?

Veltassa is used to treat hyperkalemia, a condition characterized by high potassium levels in the blood.

Who developed Veltassa?

Veltassa was initially developed by Amgen and later transferred to Relypsa, which was subsequently acquired by Vifor Pharma.

How has Veltassa's sales performance been?

Veltassa's sales have shown growth after the first year on the market, but there was a slight decline in 2021. The drug's quarterly sales have surpassed $40 million in its fourth year on the market.

What factors influence Veltassa's sales?

The drug's sales are influenced by its comparative added clinical benefit score, market competition, and external factors such as the COVID-19 pandemic.

What is the current ownership of Veltassa?

Veltassa is currently owned by CSL Vifor, following the acquisition of Vifor Pharma by CSL Limited.

Last updated: 2024-12-17

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.